50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

US Representative Wexton won't seek reelection after new diagnosis

Published 09/18/2023, 11:15 AM
Updated 09/18/2023, 05:16 PM
© Reuters. FILE PHOTO: Rep. Jennifer Wexton, D-VA questions Treasury Secretary Steven Mnuchin during testimony before the House Financial Services Committee hearing on "The Annual Testimony of the Secretary of the Treasury on the State of the International Financial

By Katharine Jackson

WASHINGTON (Reuters) -U.S. Representative Jennifer Wexton, a Virginia Democrat, said on Monday she would not seek reelection after learning that her medical condition, diagnosed earlier this year as Parkinson's Disease, was more serious than previously thought.

Wexton, who represents an area of suburban Northern Virginia outside Washington, said she would serve out her current two-year term, which ends in January 2025, but would not seek a fourth term and would instead spend time with her husband and two sons.

The 55-year-old congresswoman announced in April that she had been diagnosed with Parkinson's but would continue to work while being treated for the disease, which was affecting her speech.

Wexton said on Monday that after additional testing doctors had modified her diagnosis to a rare brain disorder called Progressive supranuclear palsy (PSP) that she described in a written statement as "a kind of Parkinson’s on steroids."

“I’ve always believed that honesty is the most important value in public service, so I want to be honest with you now, this new diagnosis is a tough one. There is no ‘getting better’ with PSP. I'll continue treatment options to manage my symptoms, but they don't work as well as they do for Parkinson's."

Progressive supranuclear palsy is caused by a deterioration of brain cells that affect body movements, according to a description by the Mayo Clinic. It causes problems with coordination, thinking, walking, eye movement, and swallowing.

"There is currently no treatment that effectively stops or slows the progression of PSP, and symptoms usually do not respond well to medications," the National Institute of Neurological Disorders and Stroke said on its website.

Wexton defeated Republican Barbara Comstock in 2018 to flip a House seat held by Republicans for decades and was reelected by a narrow margin during the 2022 midterms.

© Reuters. FILE PHOTO: Rep. Jennifer Wexton, D-VA questions Treasury Secretary Steven Mnuchin during testimony before the House Financial Services Committee hearing on

Her decision not to seek reelection could create an opportunity for Republicans to re-take the seat, without an incumbent Democrat in the race.

The seat could prove crucial as Republicans look to hold on to the narrow balance of power in the House they gained in the midterm elections and Democrats try to regain the majority.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.